Clinical trials
Phase 3 Osteoarthritis, Hip trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
| Unknown status | 4 |
| Recruiting | 3 |
| Terminated | 3 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 5 |
| Johnson & Johnson Consumer and Personal Products Worldwide | 3 |
| Alza Corporation, DE, USA | 2 |
| Regeneron Pharmaceuticals | 2 |
| Abbott | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Baxter Healthcare Corporation | 1 |
| CHU de Reims | 1 |
| Daiichi Sankyo | 1 |
| DePuy Mitek | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Osteoarthritis, Hip | 40 |
| Osteoarthritis, Knee | 18 |
| Osteoarthritis | 14 |
| Pain | 5 |
| Arthritis | 2 |
| Chronic Pain | 2 |
| Acute Pain | 1 |
| Agnosia | 1 |
| Arthralgia | 1 |
| Back Pain | 1 |
Trials
Showing 51 to 40 of 40. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.